Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical diltiazem versus botulinum toxin injection after Milligan-Morgan hemorrhoidectomy
IRCT20241022063459N1Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hemorrhoid comparing Topical diltiazem, Local botulinum toxin injection and Vaseline placebo control (3 arms). Primary endpoint: Comparison of the effect of topical diltiazem with botulinum toxin injection. Started Sep 2026; status: recruiting.
02
Drugs
diltiazembotulinum toxin type Apetrolatum
03
Conditions
hemorrhoid
Beyond the preview
Go deeper on IRCT20241022063459N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241022063459N1.